Gastroenterology
Volume 136, Issue 5 , Pages 1593-1600 , May 2009

Statin Use and the Risk of Cholecystectomy in Women

  • Chung–Jyi Tsai

      Affiliations

    • Division of Digestive Diseases and Nutrition, University of Kentucky Medical Center, Lexington, Kentucky
    • Channing Laboratory, Department of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts
    • Corresponding Author InformationCorrespondence Address correspondence to: Chung–Jyi Tsai, MD, ScD, Division of Digestive Diseases and Nutrition, University of Kentucky Medical Center, 800 Rose Street, Lexington, Kentucky 40536-0298. fax: (859) 257-8860
    • ,
  • Michael F. Leitzmann

      Affiliations

    • Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland
    • ,
  • Walter C. Willett

      Affiliations

    • Channing Laboratory, Department of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts
    • Departments of Nutrition and Epidemiology, Harvard School of Public Health, Boston, Massachusetts
    • ,
  • Edward L. Giovannucci

      Affiliations

    • Channing Laboratory, Department of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts
    • Departments of Nutrition and Epidemiology, Harvard School of Public Health, Boston, Massachusetts

Received 10 November 2008 ,Accepted 22 January 2009.

References 

  1. Beckingham IJ. ABC of diseases of liver, pancreas, and biliary system (Gallstone disease). BMJ. 2001;322:91–94
  2. National Center for Health Statistics: 2000. National hospital discharge survey. Advance Data from Vital and Health Statistics, Hyattsville, MD.
  3. Kang JY, Ellis C, Majeed A, et al. Gallstones—an increasing problem: a study of hospital admissions in England between 1989/1990 and 1999/2000. Aliment Pharmacol Ther. 2003;17:561–569
  4. Dowling RH. Pathogenesis of gallstones. Aliment Pharmacol Ther. 2000;14(Suppl 2):39–47
  5. Donovan JM, Konikoff FM. Gallstone disease: pathogenesis and treatment. In:  Schiff ER,  Sorrell MF,  Maddrey WC editor. Schiff's diseases of the liver. 10th ed.. Philadelphia: Lippincott Williams & Wilkins; 2007;p. 639–663
  6. Tazuma S, Yamashita G, Ochi H, et al. Effects of cerivastatin sodium, a new HMG-CoA reductase inhibitor, on biliary lipid metabolism in patients with hypercholesterolemia. Clin Ther. 1998;20:477–485
  7. Tazuma S, Kajiyama G, Mizuno T, et al. A combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than is ursodeoxycholic acid monotherapy. J Clin Gastroenterol. 1998;26:287–291
  8. Tazuma S, Takizawa I, Kunita T, et al. Effects of long-term treatment with low-dose pravastatin on biliary lipid and bile acid composition in patients with nonfamilial hyperlipoproteinemia. Metabolism. 1995;44:1410–1412
  9. Hawk E, Viner JL. Statins and cancer—beyond the “one drug, one disease” model. N Engl J Med. 2005;352:2238–2239
  10. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352:2184–2192
  11. Hoffmann P, Roumeguere T, Schulman C, et al. Use of statins and outcome of BCG treatment for bladder cancer. N Engl J Med. 2006;355:2705–2707
  12. Lubitz SA, Pinney S, Wisnivesky JP, et al. Statin therapy associated with a reduced risk of chronic renal failure after cardiac transplantation. J Heart Lung Transplant. 2007;26:264–272
  13. Kallien G, Lange K, Stange EF, et al. The pravastatin-induced decrease of biliary cholesterol secretion is not directly related to an inhibition of cholesterol synthesis in humans. Hepatology. 1999;30:14–20
  14. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297:499–508
  15. Rogers SL, Magliano DJ, Levison DB, et al. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. Clin Ther. 2007;29:242–252
  16. Mitchell JC, Logan GM, Stone BG, et al. Effects of lovastatin on biliary lipid secretion and bile acid metabolism in humans. J Lipid Res. 1991;32:71–78
  17. Duane WC, Hunninghake DB, Freeman ML, et al. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology. 1988;8:1147–1150
  18. Hoogerbrugge-vd Linden N, de Rooy FW, Jansen H, et al. Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia. Gut. 1990;31:348–350
  19. Porsch-Ozcurumez M, Hardt PD, Schnell-Kretschmer H, et al. Effects of fluvastatin on biliary lipids in subjects with an elevated cholesterol saturation index. Eur J Clin Pharmacol. 2001;56:873–879
  20. Saunders KD, Cates JA, Abedin MZ, et al. Lovastatin inhibits gallstone formation in the cholesterol-fed prairie dog. Ann Surg. 1991;214:149–154
  21. Tazuma S, Hatsushika S, Aihara N, et al. Inhibitory effects of pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in prairie dogs. Digestion. 1992;51:179–184
  22. Abedin MZ, Narins SC, Park EH, et al. Lovastatin alters biliary lipid composition and dissolves gallstones: a long-term study in prairie dogs. Dig Dis Sci. 2002;47:2192–2210
  23. Smit JW, van Erpecum KJ, Renooij W, et al. The effects of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease. Hepatology. 1995;21:1523–1529
  24. Smit JW, van Erpecum KJ, Stolk MF, et al. Successful dissolution of cholesterol gallstone during treatment with pravastatin. Gastroenterology. 1992;103:1068–1070
  25. Smith JL, Roach PD, Wittenberg LN, et al. Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones. J Gastroenterol Hepatol. 2000;15:871–879
  26. Colditz GA, Manson DM, Hankinson SE. The Nurses' Health Study: 20-year contribution to the understanding of health among women. J Women's Health. 1997;6:49–62
  27. Lemaitre RN, Furberg CD, Newman AB, et al. Time trends in the use of cholesterol-lowering agents in older adults: the Cardiovascular Health Study. Arch Intern Med. 1998;158:1761–1768
  28. Siegel D, Lopez J, Meier J. Use of cholesterol-lowering medications in the United States from 1991 to 1997. Am J Med. 2000;108:496–499
  29. Willett WC. Nutritional epidemiology. 2nd ed.. New York: Oxford University Press; 1998;
  30. US Department of Agriculture. Composition of foods-raw, processed, and prepared, 1963-1992 (Agricultural handbook no. 8 series). Washington, DC: Department of Agriculture, US Government Printing Office; 1993;
  31. Leitzmann MF, Rimm EB, Willett WC, et al. Recreational physical activity and the risk of cholecystectomy in women. N Engl J Med. 1999;341:777–784
  32. Maclure KM, Hayes KC, Colditz GA, et al. Weight, diet, and the risk of symptomatic gallstones in middle-aged women. N Engl J Med. 1989;321:563–569
  33. Sleisenger MH, Fordtran JS. Gastrointestinal and liver disease: pathophysiology, diagnosis, management. Philadelphia: WB Saunders; 2002;
  34. Rothman KJ, Greenland S, Lash TL. Modern epidemiology. Philadelphia: Lippincott Williams & Wilkins; 2008;
  35. Cox DR, Oakes D. Analysis of survival data. London: Chapman & Hall; 1984;
  36. Flanders WD, Khoury MJ. Indirect assessment of confounding: graphic description and limits on effect of adjusting for covariates. Epidemiology. 1990;1:239–246
  37. Smit JW, Van Erpecum KJ, Portincasa P, et al. Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia. Gut. 1995;37:654–659
  38. Sharma BC, Agarwal DK, Baijal SS, et al. Pravastatin has no effect on bile lipid composition, nucleation time, and gallbladder motility in persons with normal levels of cholesterol. J Clin Gastroenterol. 1997;25:433–436
  39. Smit JW, Van Erpecum KJ, Gadella MM, et al. Does the HMG-CoA reductase inhibitor pravastatin influence nucleation of cholesterol crystals in supersaturated model bile?. Eur J Gastroenterol Hepatol. 1996;8:197–200
  40. Saunders KD, Cates JA, Abedin MZ, et al. Lovastatin and gallstone dissolution: a preliminary study. Surgery. 1993;113:28–35
  41. Chapman BA, Burt MJ, Chisholm RJ, et al. Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor. Dig Dis Sci. 1998;43:349–353
  42. Smit JW, VanErpecum KJ, VanBerge-Henegouwen GP. Cholesterol synthesis inhibitors in cholesterol gallstone disease. Scand J Gastroenterol Suppl. 1996;218:56–60
  43. Sommeijer DW, MacGillavry MR, Meijers JC, et al. Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes. Diabetes Care. 2004;27:468–473
  44. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet. 1999;353:983–984
  45. Rosenson RS, Tangney CC. Anti-atherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998;279:1643–1650
  46. Paolisso G, Barbagallo M, Petrella G, et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis. 2000;150:121–127
  47. Paolisso G, Sgambato S, De Riu S, et al. Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics. Eur J Clin Pharmacol. 1991;40:27–31
  48. Pontrelli L, Parris W, Adeli K, et al. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism. 2002;51:334–342
  49. Nielsen S, Schmitz O, Moller N, et al. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia. 1993;36:1079–1086
  50. Gannage-Yared MH, Azar RR, Amm-Azar M, et al. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism. 2005;54:947–951
  51. Misciagna G, Guerra V, Di Leo A, et al. Insulin and gall stones: a population case control study in southern Italy. Gut. 2000;47:144–147
  52. Tsai CJ, Leitzmann MF, Willett WC, et al. Glycemic load, glycemic index, and carbohydrate intake in relation to risk of cholecystectomy in women. Gastroenterology. 2005;129:105–112
  53. Tsai CJ, Leitzmann MF, Willett WC, et al. Macronutrients and insulin resistance in cholesterol gallstone disease. Am J Gastroenterol. 2008;103:2932–2939
  54. Rimm EB, Stampfer MJ, Colditz GA, et al. Validity of self-reported waist and hip circumferences in men and women. Epidemiology. 1990;1:466–473
  55. Feskanich D, Rimm EB, Giovannucci EL, et al. Reproducibility and validity of food intake measurements from a semiquantitative food frequency questionnaire. J Am Diet Assoc. 1993;93:790–796

 Conflict of interest The authors disclose no conflicts.

 Funding Grant support for the study was provided by research grants (CA55075 and DK46200) from the National Institutes of Health.

PII: S0016-5085(09)00143-7

doi: 10.1053/j.gastro.2009.01.042

Gastroenterology
Volume 136, Issue 5 , Pages 1593-1600 , May 2009

Article Tools